AR125122A1 - Actividad antiviral de inhibidores de vps34 - Google Patents
Actividad antiviral de inhibidores de vps34Info
- Publication number
- AR125122A1 AR125122A1 ARP210103260A ARP210103260A AR125122A1 AR 125122 A1 AR125122 A1 AR 125122A1 AR P210103260 A ARP210103260 A AR P210103260A AR P210103260 A ARP210103260 A AR P210103260A AR 125122 A1 AR125122 A1 AR 125122A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- c3alkyl
- c6alkyl
- phenyl
- optionally substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos de tratamiento de infecciones virales, tales como infecciones por coronavirus, en pacientes que lo necesitan, que comprenden administrar a dichos pacientes un inhibidor de VPS34. Reivindicación 1: Un método para paliar o tratar una infección viral en un paciente que lo necesite, caracterizado porque comprende administrar al paciente una cantidad terapéuticamente eficaz de un compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable, estereoisómero, o tautómero del mismo, donde: R¹ se selecciona entre C₁-C₃alquilo y ciclopropilo; R² se selecciona entre el grupo que consiste en H, C₁-C₃haloalquilo, y C₁-C₃alquilo; A se selecciona entre: los compuestos del grupo de fórmulas (2); cada R³ se selecciona en forma independiente entre el grupo que consiste en R⁶, C₁-C₆alquilo, amino, N-C₁-C₃alquilamino, N,N-diC₁-C₃alquilamino, y C₁-C₃alcoxiC₁-C₃alquilo, donde cada uno de C₁-C₆alquilo y C₁-C₃alcoxiC₁-C₃alquilo está opcionalmente sustituido con una instancia de R⁶, y cada C₁-C₆alquilo y C₁-C₃alcoxiC₁-C₃alquilo está opcionalmente sustituido con una o más instancias independientes de halógeno; R⁴ se selecciona entre el grupo que consiste en C₁-C₆alquilo, C₁-C₆alcoxi, C₁-C₆haloalquilo, C₃-C₆cicloalquilo, y fenilo, donde fenilo está opcionalmente sustituido con una o más instancias de un sustituyente seleccionado en forma independiente entre el grupo que consiste en fluoro, cloro, metilo, metoxi, dimetilamino, trifluorometoxi, trifluorometilo, y ciclopropilo; R⁵ se selecciona entre el grupo que consiste en halógeno, C₁-C₆alquilo, C₁-C₆alcoxi, C₁-C₆haloalquilo, y C₃-C₆cicloalquilo; cada R⁶ se selecciona en forma independiente entre el grupo que consiste en fenilo, heteroarilo monocíclico, C₃-C₆cicloalquilo, y heterociclilo, donde cada fenilo, heteroarilo monocíclico, C₃-C₆cicloalquilo, y heterociclilo está opcionalmente sustituido con una o más instancias de R⁷; y cada R⁷ se selecciona en forma independiente entre el grupo que consiste en halógeno, amino, N-C₁-C₃alquilamino, N,N-diC₁-C₃alquilamino y C₁-C₃alcoxiC₁-C₃alquilo, C₁-C₃alcoxi, C₁-C₃haloalcoxi, C₃-C₆cicloalquilo, C₁-C₃haloalquilo, y C₁-C₃alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063118509P | 2020-11-25 | 2020-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125122A1 true AR125122A1 (es) | 2023-06-14 |
Family
ID=78957685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103260A AR125122A1 (es) | 2020-11-25 | 2021-11-25 | Actividad antiviral de inhibidores de vps34 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220184093A1 (es) |
| EP (1) | EP4251165A1 (es) |
| JP (1) | JP2023550641A (es) |
| CN (1) | CN117241829A (es) |
| AR (1) | AR125122A1 (es) |
| CA (1) | CA3199995A1 (es) |
| TW (1) | TW202237130A (es) |
| WO (1) | WO2022115558A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3198943A1 (en) | 2020-11-18 | 2022-05-27 | Daniel L. Flynn | Gcn2 and perk kinase inhibitors and methods of use thereof |
| US12414955B2 (en) | 2020-11-25 | 2025-09-16 | Deciphera Pharmaceuticals, Llc | Anti-viral activity of VPS34 inhibitors |
| PE20241934A1 (es) | 2021-12-09 | 2024-09-24 | Deciphera Pharmaceuticals Llc | Inhibidores de raf quinasa y metodos de uso de los mismos |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2529847A1 (en) * | 2003-06-20 | 2004-12-29 | Viral Genomix, Inc. | Antiviral compositions and methods of using the same |
| US20110142837A1 (en) * | 2007-07-20 | 2011-06-16 | Trustees Of The University Of Pennsylvania | Method Of Treating Acute Respiratory Distress Syndrome |
| EP2895170A4 (en) * | 2012-09-14 | 2016-07-20 | Childrens Medical Center | INHIBITION OF VIRAL INFECTION-RELATED ASTHMA WITH A C-KIT HEMMER |
| EP3283463B1 (en) * | 2015-04-17 | 2021-01-20 | The Trustees Of The University Of Pennsylvania | Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy |
| RS60900B1 (sr) * | 2016-02-19 | 2020-11-30 | Sprint Bioscience Ab | Jedinjenja 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisna za lečenje kancera i dijabetesa |
| CA3077489A1 (en) * | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| JP7199736B2 (ja) * | 2017-08-23 | 2023-01-06 | スプリント バイオサイエンス アクティエボラーグ | モルホリニルピリドン化合物 |
| PT3672948T (pt) * | 2017-08-23 | 2022-11-07 | Sprint Bioscience Ab | Compostos de piridinamina-piridona e pirimidinamina-piridona |
| CN108310384B (zh) * | 2018-02-05 | 2021-06-15 | 苏州大学 | Pi3k抑制剂在制备治疗血小板数量减少相关疾病药物中的用途 |
| JP7116256B1 (ja) * | 2020-04-02 | 2022-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片 |
-
2021
- 2021-11-24 CN CN202180090242.2A patent/CN117241829A/zh active Pending
- 2021-11-24 US US17/534,771 patent/US20220184093A1/en not_active Abandoned
- 2021-11-24 WO PCT/US2021/060758 patent/WO2022115558A1/en not_active Ceased
- 2021-11-24 EP EP21827785.3A patent/EP4251165A1/en not_active Withdrawn
- 2021-11-24 JP JP2023531514A patent/JP2023550641A/ja active Pending
- 2021-11-24 CA CA3199995A patent/CA3199995A1/en active Pending
- 2021-11-25 TW TW110143939A patent/TW202237130A/zh unknown
- 2021-11-25 AR ARP210103260A patent/AR125122A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP4251165A1 (en) | 2023-10-04 |
| CA3199995A1 (en) | 2022-06-02 |
| US20220184093A1 (en) | 2022-06-16 |
| TW202237130A (zh) | 2022-10-01 |
| WO2022115558A1 (en) | 2022-06-02 |
| JP2023550641A (ja) | 2023-12-04 |
| CN117241829A (zh) | 2023-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| AR125122A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| PE20221339A1 (es) | Inhibidores de parp1 | |
| AR127235A1 (es) | Pirazoloquinolinas inhibidoras de kras | |
| AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR111820A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación de virus del dengue | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| CL2021003202A1 (es) | Compuestos de pirrolidina | |
| MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| AR111878A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| RU2013119607A (ru) | Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| MX2024002538A (es) | Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t. | |
| PE20180232A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue | |
| AR125118A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| AR081261A1 (es) | Metodos para tratar afecciones virales | |
| JP2017522273A5 (es) | ||
| AR119614A1 (es) | Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma | |
| AR125120A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| AR125117A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| AR130094A1 (es) | Inhibidores de inflamasoma nlrp3 | |
| AR115965A1 (es) | Derivados heteroaromáticos de carboxamida como inhibidores de la calicreína plasmática | |
| CO2024010542A2 (es) | Inhibidores de apol1 y métodos de uso | |
| EA201270266A1 (ru) | Гетероциклические соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |